Cannabis hopes for drug firm A prescription cannabis drug made by <LOCATION>UK</LOCATION> biotech firm GW Pharmaceuticals is set to be approved in <LOCATION>Canada</LOCATION> . 
The drug is used to treat the central nervous system and alleviate the symptoms of multiple sclerosis -LRB- MS -RRB- . 
A few weeks ago , shares in GW Pharma lost a third of their value after <LOCATION>UK</LOCATION> regulators said they wanted more evidence about the drug 's benefits . 
But now Canadian authorities have said the Sativex drug will be considered for approval . 
Approximately 50,000 people in <LOCATION>Canada</LOCATION> have been diagnosed with MS and 85,000 people are suffering from the condition in the <LOCATION>UK</LOCATION> . 
Many patients already smoke cannabis to relieve their symptoms . 
Now , GW Pharma 's Sativex mouth spray could be legally available to MS sufferers in <LOCATION>Canada</LOCATION> within the next few months . 
This will be the first time a cannabis-based drug has been approved anywhere in the world , representing a landmark for GW Pharma and for patients with MS. Final approval in <LOCATION>Canada</LOCATION> should now be little more than a formality , analysts said , and the company expects full approval for Sativex early in 2005 . 
`` We are delighted to receive this qualifying notice from Health Canada and look forward to receiving regulatory approval for Sativex in <LOCATION>Canada</LOCATION> in the early part of 2005 , '' said GW Pharma executive chairman Dr Geoffrey Guy . 
The <LOCATION>UK</LOCATION> government granted GW Pharma a licence to grow the cannabis plant for medical research purposes . 
Satifex consists of a cannabis extract containing tetrahydrocannabinol and cannabidiol , a cocktail that has also proved effective in treating patients with arthritis . 
Thousands of plants are grown at a secret location somewhere in the English countryside . 
Despite hopes of regulatory approval last year , a series of delays has put back Sativex 's launch in the <LOCATION>UK</LOCATION> . 
The latest news sent shares in GW Pharma up 8.5 p , or 8.1 % , to 113.5 p. 
